These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19816876)

  • 1. Risk factor adjustment in marginal structural model estimation of optimal treatment regimes.
    Moodie EE
    Biom J; 2009 Oct; 51(5):774-88. PubMed ID: 19816876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting treatment-effect estimates with heterogeneity and choice: simulation model results.
    Brooks JM; Fang G
    Clin Ther; 2009 Apr; 31(4):902-19. PubMed ID: 19446162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mis-specification of the treatment model on estimates from a marginal structural model.
    Lefebvre G; Delaney JA; Platt RW
    Stat Med; 2008 Aug; 27(18):3629-42. PubMed ID: 18254127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marginal structural models for the estimation of direct and indirect effects.
    VanderWeele TJ
    Epidemiology; 2009 Jan; 20(1):18-26. PubMed ID: 19234398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marginal structural models for estimating principal stratum direct effects under the monotonicity assumption.
    Chiba Y
    Biom J; 2011 Nov; 53(6):1025-34. PubMed ID: 22020774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures.
    Hernán MA; Brumback BA; Robins JM
    Stat Med; 2002 Jun; 21(12):1689-709. PubMed ID: 12111906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting.
    Pullenayegum EM; Lam C; Manlhiot C; Feldman BM
    J Clin Epidemiol; 2008 Sep; 61(9):875-81. PubMed ID: 18486447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is risk-adjustor selection more important than statistical approach for provider profiling? Asthma as an example.
    Huang IC; Dominici F; Frangakis C; Diette GB; Damberg CL; Wu AW
    Med Decis Making; 2005; 25(1):20-34. PubMed ID: 15673579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The performance of different propensity score methods for estimating marginal odds ratios.
    Austin PC
    Stat Med; 2007 Jul; 26(16):3078-94. PubMed ID: 17187347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk adjustment and outcome research. Part I.
    Arcà M; Fusco D; Barone AP; Perucci CA
    J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):682-90. PubMed ID: 16932082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity and the interpretation of treatment effect estimates from risk adjustment and instrumental variable methods.
    Brooks JM; Chrischilles EA
    Med Care; 2007 Oct; 45(10 Supl 2):S123-30. PubMed ID: 17909370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized modeling approaches to risk adjustment of skewed outcomes data.
    Manning WG; Basu A; Mullahy J
    J Health Econ; 2005 May; 24(3):465-88. PubMed ID: 15811539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The performance of different propensity-score methods for estimating relative risks.
    Austin PC
    J Clin Epidemiol; 2008 Jun; 61(6):537-45. PubMed ID: 18471657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies.
    Suarez D; Haro JM; Novick D; Ochoa S
    J Clin Epidemiol; 2008 Jun; 61(6):525-30. PubMed ID: 18471655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on the use of unbiased estimating equations to estimate correlation in analysis of longitudinal trials.
    Sun W; Shults J; Leonard M
    Biom J; 2009 Feb; 51(1):5-18. PubMed ID: 19197953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An application of propensity score matching using claims data.
    Seeger JD; Williams PL; Walker AM
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):465-76. PubMed ID: 15651087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect modification by time-varying covariates.
    Robins JM; Hernán MA; Rotnitzky A
    Am J Epidemiol; 2007 Nov; 166(9):994-1002; discussion 1003-4. PubMed ID: 17875581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marginal analysis of correlated failure time data with informative cluster sizes.
    Cong XJ; Yin G; Shen Y
    Biometrics; 2007 Sep; 63(3):663-72. PubMed ID: 17825000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marginal structural models for estimating effect modification.
    Chiba Y; Azuma K; Okumura J
    Ann Epidemiol; 2009 May; 19(5):298-303. PubMed ID: 19362275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.